P11836 (CD20_HUMAN) Reviewed, UniProtKB/Swiss-Prot
Last modified
May 1, 2013.
Version 134.
History...
Names·Attributes·General annotation·Ontologies·Sequence annotation·Sequences·References·Web links·Cross-refs·Entry info·DocumentsCustomize order
Names·Attributes·General annotation·Ontologies·Sequence annotation·Sequences·References·Web links·Cross-refs·Entry info·DocumentsCustomize orderNames and origin
| Protein names | Recommended name: B-lymphocyte antigen CD20 Alternative name(s): B-lymphocyte surface antigen B1 Bp35 Leukocyte surface antigen Leu-16 Membrane-spanning 4-domains subfamily A member 1 CD_antigen=CD20 | ||||
| Gene names |
| ||||
| Organism | Homo sapiens (Human) [Reference proteome] | ||||
| Taxonomic identifier | 9606 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo![]() |
Protein attributes
| Sequence length | 297 AA. |
| Sequence status | Complete. |
| Protein existence | Evidence at protein level |
General annotation (Comments)
| Function | This protein may be involved in the regulation of B-cell activation and proliferation. |
| Subcellular location | Cell membrane; Multi-pass membrane protein. Cell membrane; Lipid-anchor Ref.11. |
| Tissue specificity | Expressed on B-cells. |
| Post-translational modification | Phosphorylated. Might be functionally regulated by protein kinase(s). |
| Involvement in disease | Immunodeficiency, common variable, 5 (CVID5) [MIM:613495]: A primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low. |
| Pharmaceutical use | Monoclonal antibodies (mAb) against CD20 are used to treat B-cell non-Hodgkin lymphoma (NHL). These antibodies include Rituximab (Mabthera), Britumomab (Zevalin) and Tositumomab (Bexxar). CD20 engaged by mAb can generate transmembrane signals capable of directly controlling cell growth and triggering cell death in certain tumors. Alternatively, mAb can mediate complement-dependent cytotoxicity. |
| Sequence similarities | Belongs to the MS4A family. |
| Caution | Epitope 1, mapped in Ref.8, is predicted to be buried in the membrane. Its accessibility to the extracellular space, and thus to antibody recognition, is not explained. |
Ontologies
| Keywords | |
|---|---|
| Biological process | B-cell activation |
| Cellular component | Cell membrane Membrane |
| Domain | Transmembrane Transmembrane helix |
| PTM | Disulfide bond Lipoprotein Palmitate Phosphoprotein |
| Technical term | 3D-structure Complete proteome Pharmaceutical Reference proteome |
| Gene Ontology (GO) | |
| Biological_process | B cell activation Inferred from electronic annotation. Source: UniProtKB-KW immune responseTraceable author statement PubMed 7920628. Source: ProtInc |
| Cellular_component | external side of plasma membrane Inferred from electronic annotation. Source: Compara integral to plasma membraneTraceable author statement PubMed 1535625. Source: ProtInc nucleolusInferred from direct assay. Source: HPA |
| Complete GO annotation... | |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | ||||||||
Molecule processing | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chain | 1 – 297 | 297 | B-lymphocyte antigen CD20 | PRO_0000158627 | |||||||||
Regions | |||||||||||||
| Topological domain | 1 – 56 | 56 | Cytoplasmic Potential | ||||||||||
| Transmembrane | 57 – 78 | 22 | Helical; Potential | ||||||||||
| Topological domain | 79 – 84 | 6 | Extracellular Potential | ||||||||||
| Transmembrane | 85 – 105 | 21 | Helical; Potential | ||||||||||
| Topological domain | 106 – 120 | 15 | Cytoplasmic Potential | ||||||||||
| Transmembrane | 121 – 141 | 21 | Helical; Potential | ||||||||||
| Topological domain | 142 – 188 | 47 | Extracellular Potential | ||||||||||
| Transmembrane | 189 – 209 | 21 | Helical; Potential | ||||||||||
| Topological domain | 210 – 297 | 88 | Cytoplasmic Potential | ||||||||||
| Region | 74 – 80 | 7 | Epitope 1 | ||||||||||
| Region | 146 – 160 | 15 | Epitope 2 | ||||||||||
| Region | 168 – 175 | 8 | Epitope 3 (recognized by antibodies, including Rituximab) | ||||||||||
Amino acid modifications | |||||||||||||
| Lipidation | 111 | 1 | S-palmitoyl cysteine Probable | ||||||||||
| Lipidation | 220 | 1 | S-palmitoyl cysteine Ref.11 | ||||||||||
| Disulfide bond | 167 ↔ 183 | Ref.12 | |||||||||||
Experimental info | |||||||||||||
| Mutagenesis | 159 | 1 | T → K: Abrogates recognition by some antibodies; when associated with D-163 and D-166. Slight decrease of rituximab binding; when associated with D-163 and D-166. Ref.8 | ||||||||||
| Mutagenesis | 163 | 1 | N → D: Decreased binding of some antibodies. No effect on rituximab binding. Ref.8 | ||||||||||
| Mutagenesis | 166 | 1 | N → D: Decreased binding of some antibodies. No effect on rituximab binding. Ref.8 | ||||||||||
| Mutagenesis | 170 | 1 | A → S: Abrogates recognition by therapeutic antibodies, including rituximab; when associated with S-172. Ref.8 | ||||||||||
| Mutagenesis | 172 | 1 | P → S: Marked reduction in rituximab binding. Abrogates recognition by antibodies, including rituximab; when associated with S-170. Ref.8 | ||||||||||
| Sequence conflict | 13 | 1 | P → L in CAA30179. Ref.3 | ||||||||||
| Sequence conflict | 13 | 1 | P → L in CAA30180. Ref.3 | ||||||||||
| Sequence conflict | 71 | 1 | M → I in AAA88911. Ref.4 | ||||||||||
Secondary structure | |||||||||||||
Helix Strand Turn | |||||||||||||
| Helix | 172 – 174 | 3 | |||||||||||
| Helix | 178 – 185 | 8 | |||||||||||
Sequences
| ||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein." Stamenkovic I., Seed B. J. Exp. Med. 167:1975-1980(1988) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA]. |
| [2] | "Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes." Tedder T.F., Streuli M., Schlossman S.F., Saito H. Proc. Natl. Acad. Sci. U.S.A. 85:208-212(1988) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA]. |
| [3] | "Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains." Einfeld D.A., Brown J.P., Valentine M.A., Clark E.A., Ledbetter J.A. EMBO J. 7:711-717(1988) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA]. |
| [4] | "Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1)." Tedder T.F., Klejman G., Schlossman S.F., Saito H. J. Immunol. 142:2560-2568(1989) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]. |
| [5] | "Human chromosome 11 DNA sequence and analysis including novel gene identification." Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K., Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G. Sakaki Y.Nature 440:497-500(2006) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. |
| [6] | Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., Turner R. Venter J.C.Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. |
| [7] | "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. Tissue: Lymph. |
| [8] | "The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20." Teeling J.L., Mackus W.J.M., Wiegman L.J.J.M., van den Brakel J.H.N., Beers S.A., French R.R., van Meerten T., Ebeling S., Vink T., Slootstra J.W., Parren P.W.H.I., Glennie M.J., van de Winkel J.G.J. J. Immunol. 177:362-371(2006) [PubMed] [Europe PMC] [Abstract] Cited for: EPITOPE MAPPING, MUTAGENESIS OF THR-159; ASN-163; ASN-166; ALA-170 AND PRO-172. |
| [9] | "Phosphorylation analysis of primary human T lymphocytes using sequential IMAC and titanium oxide enrichment." Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J. J. Proteome Res. 7:5167-5176(2008) [PubMed] [Europe PMC] [Abstract] Cited for: IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. Tissue: T-cell. |
| [10] | "CD20 deficiency in humans results in impaired T cell-independent antibody responses." Kuijpers T.W., Bende R.J., Baars P.A., Grummels A., Derks I.A.M., Dolman K.M., Beaumont T., Tedder T.F., van Noesel C.J.M., Eldering E., van Lier R.A.W. J. Clin. Invest. 120:214-222(2010) [PubMed] [Europe PMC] [Abstract] Cited for: INVOLVEMENT IN CVID5. |
| [11] | "Proteomic analysis of S-acylated proteins in human B cells reveals palmitoylation of the immune regulators CD20 and CD23." Ivaldi C., Martin B.R., Kieffer-Jaquinod S., Chapel A., Levade T., Garin J., Journet A. PLoS ONE 7:E37187-E37187(2012) [PubMed] [Europe PMC] [Abstract] Cited for: PALMITOYLATION AT CYS-111 AND CYS-220, TOPOLOGY, SUBCELLULAR LOCATION. Tissue: B-cell. |
| [12] | "Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies." Niederfellner G., Lammens A., Mundigl O., Georges G.J., Schaefer W., Schwaiger M., Franke A., Wiechmann K., Jenewein S., Slootstra J.W., Timmerman P., Brannstrom A., Lindstrom F., Mossner E., Umana P., Hopfner K.P., Klein C. Blood 118:358-367(2011) [PubMed] [Europe PMC] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 163-187 IN COMPLEX WITH ANTIBODY, DISULFIDE BOND. |
| + | Additional computationally mapped references. |
Web resources
| Wikipedia CD20 entry |
Cross-references
Sequence databases | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMBL GenBank DDBJ | X12530 mRNA. Translation: CAA31046.1. M27394 Genomic DNA. Translation: AAA35581.1. X07203 mRNA. Translation: CAA30179.1. X07204 mRNA. Translation: CAA30180.1. L23419 L23417 Genomic DNA. Translation: AAA88911.1.M27395 Genomic DNA. No translation available. AP003127 Genomic DNA. No translation available. CH471076 Genomic DNA. Translation: EAW73889.1. BC002807 mRNA. Translation: AAH02807.1. | ||||||||||||||||||||||||||||||
| IPI | IPI00007880. | ||||||||||||||||||||||||||||||
| PIR | A30586. | ||||||||||||||||||||||||||||||
| RefSeq | NP_068769.2. NM_021950.3. NP_690605.1. NM_152866.2. | ||||||||||||||||||||||||||||||
| UniGene | Hs.712553. | ||||||||||||||||||||||||||||||
3D structure databases | |||||||||||||||||||||||||||||||
| PDBe RCSB PDB PDBj |
| ||||||||||||||||||||||||||||||
| ProteinModelPortal | P11836. | ||||||||||||||||||||||||||||||
| ModBase | Search... | ||||||||||||||||||||||||||||||
Protein-protein interaction databases | |||||||||||||||||||||||||||||||
| IntAct | P11836. 2 interactions. | ||||||||||||||||||||||||||||||
| STRING | 9606.ENSP00000314620. | ||||||||||||||||||||||||||||||
Protein family/group databases | |||||||||||||||||||||||||||||||
| TCDB | 1.A.37.1.1. CD20 Ca2+ channel (CD20) family. | ||||||||||||||||||||||||||||||
PTM databases | |||||||||||||||||||||||||||||||
| PhosphoSite | P11836. | ||||||||||||||||||||||||||||||
Polymorphism databases | |||||||||||||||||||||||||||||||
| DMDM | 115968. | ||||||||||||||||||||||||||||||
Proteomic databases | |||||||||||||||||||||||||||||||
| PaxDb | P11836. | ||||||||||||||||||||||||||||||
| PRIDE | P11836. | ||||||||||||||||||||||||||||||
Protocols and materials databases | |||||||||||||||||||||||||||||||
| DNASU | 931. | ||||||||||||||||||||||||||||||
| StructuralBiologyKnowledgebase | Search... | ||||||||||||||||||||||||||||||
Genome annotation databases | |||||||||||||||||||||||||||||||
| Ensembl | ENST00000345732; ENSP00000314620; ENSG00000156738. ENST00000389939; ENSP00000374589; ENSG00000156738. ENST00000524807; ENSP00000433179; ENSG00000156738. ENST00000534668; ENSP00000433277; ENSG00000156738. | ||||||||||||||||||||||||||||||
| GeneID | 931. | ||||||||||||||||||||||||||||||
| KEGG | hsa:931. | ||||||||||||||||||||||||||||||
| UCSC | uc001npp.3. human. | ||||||||||||||||||||||||||||||
Organism-specific databases | |||||||||||||||||||||||||||||||
| CTD | 931. | ||||||||||||||||||||||||||||||
| GeneCards | GC11P060225. | ||||||||||||||||||||||||||||||
| HGNC | HGNC:7315. MS4A1. | ||||||||||||||||||||||||||||||
| HPA | CAB000015. HPA014341. HPA014391. | ||||||||||||||||||||||||||||||
| MIM | 112210. gene. 613495. phenotype. | ||||||||||||||||||||||||||||||
| neXtProt | NX_P11836. | ||||||||||||||||||||||||||||||
| Orphanet | 99831. Common variable immunodeficiency due to an intrinsic T cell defect. | ||||||||||||||||||||||||||||||
| PharmGKB | PA31111. | ||||||||||||||||||||||||||||||
| GenAtlas | Search... | ||||||||||||||||||||||||||||||
Phylogenomic databases | |||||||||||||||||||||||||||||||
| eggNOG | NOG43290. | ||||||||||||||||||||||||||||||
| HOGENOM | HOG000111479. | ||||||||||||||||||||||||||||||
| HOVERGEN | HBG048815. | ||||||||||||||||||||||||||||||
| InParanoid | P11836. | ||||||||||||||||||||||||||||||
| KO | K06466. | ||||||||||||||||||||||||||||||
| OMA | VMLIFAF. | ||||||||||||||||||||||||||||||
| OrthoDB | EOG4MW86T. | ||||||||||||||||||||||||||||||
Gene expression databases | |||||||||||||||||||||||||||||||
| ArrayExpress | P11836. | ||||||||||||||||||||||||||||||
| Bgee | P11836. | ||||||||||||||||||||||||||||||
| CleanEx | HS_MS4A1. | ||||||||||||||||||||||||||||||
| Genevestigator | P11836. | ||||||||||||||||||||||||||||||
| GermOnline | ENSG00000156738. Homo sapiens. | ||||||||||||||||||||||||||||||
Family and domain databases | |||||||||||||||||||||||||||||||
| InterPro | IPR007237. CD20-like. [Graphical view] | ||||||||||||||||||||||||||||||
| Pfam | PF04103. CD20. 1 hit. [Graphical view] | ||||||||||||||||||||||||||||||
| ProtoNet | Search... | ||||||||||||||||||||||||||||||
Other | |||||||||||||||||||||||||||||||
| ChEMBL | CHEMBL2058. | ||||||||||||||||||||||||||||||
| DrugBank | DB00078. Ibritumomab. DB00073. Rituximab. DB00081. Tositumomab. | ||||||||||||||||||||||||||||||
| EvolutionaryTrace | P11836. | ||||||||||||||||||||||||||||||
| GenomeRNAi | 931. | ||||||||||||||||||||||||||||||
| NextBio | 3860. | ||||||||||||||||||||||||||||||
| SOURCE | Search... | ||||||||||||||||||||||||||||||
Entry information
| Entry name | CD20_HUMAN | ||||||||
| Accession | Primary (citable) accession number: P11836 Secondary accession number(s): A6NMS4, P08984, Q13963 | ||||||||
| Entry history |
| ||||||||
| Entry status | Reviewed (UniProtKB/Swiss-Prot) | ||||||||
| Annotation program | Chordata Protein Annotation Program | ||||||||
| Disclaimer | Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care. | ||||||||
Relevant documents
| Human cell differentiation molecules CD nomenclature of surface proteins of human leucocytes and list of entries |
| Human chromosome 11 Human chromosome 11: entries, gene names and cross-references to MIM |
| MIM cross-references Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot |
| PDB cross-references Index of Protein Data Bank (PDB) cross-references |
| SIMILARITY comments Index of protein domains and families |

Clusters with
